[1]Schmidt M I, Hadji-Georgopoulos A, Rendell M, et al. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation[J]. Diabetes Care, 1981, 4(6): 579-585.
[2]Monnier L, Colette C, Sardinoux M, et al. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age[J]. Diabetes Care, 2012, 35(12): 2597-2599.
[3]中华医学会糖尿病学分会. 中国持续葡萄糖监测临床应用指南(2017年版)[J]. 中华糖尿病杂志, 2017, 9(11): 667-675.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[5] 《中国老年2 型糖尿病防治临床指南》编写组. 中国老年2 型糖尿病防治临床指南(2022 年版)[J]. 中国糖尿病杂志, 2022, 30 ( 1): 2 - 51.
[6]Monnier L, Colette C, Owens D. Glucose variability: do we have to revisit the profusion of definitions to avoid confusion?[J]. Diabetes Metab, 2018, 44(2): 97-100.
[7]Ostrovski I, Lovblom L E, Scarr D, et al. Analysis of prevalence, magnitude and timing of the dawn phenomenon in adults and adolescents with type 1 diabetes: descriptive analysis of 2 insulin pump trials[J]. Can J Diabetes, 2020, 44(3): 229-235.
[8]Monnier L, Colette C, Dejager S, et al. The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?[J]. Diabetes Metab, 2015, 41(2): 132-137.
[9]Peng F, Li X, Xiao F, et al. Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon[J]. Trends Neurosci, 2022, 45(6): 471-482.
[10]Shih K C, Hsieh S H, Kwok C F, et al. Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes[J]. Growth Factors, 2013, 31(2): 66-73.
[11]Takahashi N, Chujo D, Kajio H, et al. Contribution of pancreatic α-cell function to insulin sensitivity and glycemic variability in patients with type 1 diabetes[J]. J Diabetes Investig, 2019, 10(3): 690-698.
[12]Peng F, Li X, Xiao F, et al. Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon[J]. Trends Neurosci, 2022, 45(6): 471-482.
[13]Li C, Ma X J, Yin J, et al. The dawn phenomenon across the glycemic continuum: implications for defining dysglycemia[J]. Diabetes Res Clin Pract, 2020, 166: 108308.
[14]Monnier L, Colette C, Dejager S, et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?[J]. Diabetes Care, 2013, 36(12): 4057-4062.
[15]Klimontov V V, Saik O V, Korbut A I. Glucose variability: how does it work?[J]. Int J Mol Sci, 2021, 22(15): 7783.
[16]Mizushima N, Levine B. Autophagy in human diseases[J]. N Engl J Med, 2020, 383(16): 1564-1576.
[17]Wu N, Shen H T, Liu H N, et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo[J]. Cardiovasc Diabetol, 2016, 15(1): 109.
[18]Zinman B, Marso S P, Poulter N R, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)[J]. Diabetologia, 2018, 61(1): 48-57.
[19]Prentice J C, Pizer S D, Conlin P R. Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with type 2 diabetes[J]. Diabet Med, 2016, 33(12): 1640-1648.
[20]Jun J E, Lee S E, Lee Y B, et al. Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients[J]. Cardiovasc Diabetol, 2017, 16(1): 127.
[21]Takao T, Suka M, Yanagisawa H, et al. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes[J]. Diabetes Res Clin Pract, 2017, 128: 15-23.
[22]Yapanis M, James S, Craig M E, et al. Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring[J]. J Clin Endocrinol Metab, 2022, 107(6): e2221-e2236.
[23]Dorajoo S R, Ng J S L, Goh J H F, et al. HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years[J]. Diabetes Res Clin Pract, 2017, 128: 32-39.
[24]Lee M Y, Hsiao P J, Huang Y T, et al. Greater HbA1c variability is associated with increased cardiovascular events in type 2 diabetes patients with preserved renal function, but not in moderate to advanced chronic kidney disease[J]. PLoS One, 2017, 12(6): e0178319.
[25]Porcellati F, Lucidi P, Bolli G B, et al. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes[J]. Diabetes Care, 2013, 36(12): 3860-3862.
[26]Monnier L, Colette C, Dejager S, et al. “Mild dysglycemia” in type 2 diabetes: to be neglected or not?[J]. J Diabetes Complications, 2015, 29(3): 451-458.
[27]Rizzo M R, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-Ⅳ inhibitio[J]. Diabetes Care, 2012, 35(10): 2076-2082.
[28]Wang J S, Lee I T, Lee W J, et al. The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs[J]. Ther Adv Chronic Dis, 2021, 12: 20406223211033674.
[29]Zheng X, Qi Y Y, Bi L N, et al. Effects of exercise on blood glucose and glycemic variability in type 2 diabetic patients with dawn phenomenon[J]. Biomed Res Int, 2020, 2020: 6408724.
[30]Paing A C, McMillan K A, Kirk A F, et al. Impact of free-living pattern of sedentary behaviour on intra-day glucose regulation in type 2 diabetes[J]. Eur J Appl Physiol, 2020, 120(1): 171-179.
|